Toll Free: 1-888-928-9744

Spherix Incorporated - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 32 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Spherix Incorporated - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Spherix Incorporated - Product Pipeline Review - 2014', provides an overview of the Spherix Incorporated's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Spherix Incorporated's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Spherix Incorporated including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Spherix Incorporated's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Spherix Incorporated's pipeline products

Reasons to buy

- Evaluate Spherix Incorporated's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Spherix Incorporated in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Spherix Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Spherix Incorporated and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Spherix Incorporated
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Spherix Incorporated and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Spherix Incorporated Snapshot 5
Spherix Incorporated Overview 5
Key Information 5
Key Facts 5
Spherix Incorporated - Research and Development Overview 6
Key Therapeutic Areas 6
Spherix Incorporated - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Spherix Incorporated - Pipeline Products Glance 12
Spherix Incorporated - Clinical Stage Pipeline Products 12
Phase I Products/Combination Treatment Modalities 12
Spherix Incorporated - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Spherix Incorporated - Drug Profiles 14
SPX-10624258 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
(SPX-106 + D-tagatose) 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
SPX-100 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
SPX-7233801 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
SPX-8522876 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
SPX-8818309 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
SPX-8818440 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Spherix Incorporated - Pipeline Analysis 22
Spherix Incorporated - Pipeline Products by Target 22
Spherix Incorporated - Pipeline Products by Molecule Type 23
Spherix Incorporated - Pipeline Products by Mechanism of Action 24
Spherix Incorporated - Recent Pipeline Updates 25
Spherix Incorporated - Company Statement 26
Spherix Incorporated - Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32
List of Tables
Spherix Incorporated, Key Information 5
Spherix Incorporated, Key Facts 5
Spherix Incorporated - Pipeline by Indication, 2014 8
Spherix Incorporated - Pipeline by Stage of Development, 2014 9
Spherix Incorporated - Monotherapy Products in Pipeline, 2014 10
Spherix Incorporated - Combination Treatment Modalities in Pipeline, 2014 11
Spherix Incorporated - Phase I, 2014 12
Spherix Incorporated - Preclinical, 2014 13
Spherix Incorporated - Pipeline by Target, 2014 22
Spherix Incorporated - Pipeline by Molecule Type, 2014 23
Spherix Incorporated - Pipeline Products by Mechanism of Action, 2014 24
Spherix Incorporated - Recent Pipeline Updates, 2014 25
Spherix Incorporated, Subsidiaries 30 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify